Pharma news
Pharma
Coherus Biosciences has signed a deal with Chinese biopharmaceutical company Shanghai Junshi Biosciences for the development and commercialisation rights to toripalimab, Junshi’s PD-1 inhibitor, in the US and Canada. 4 February 2021
Pharma
Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences. 4 February 2021
Pharma
A decision by the Supreme Court over the assignor estoppel doctrine could have far-reaching implications for patent law, argue Jeffrey D Morton, Zachary Schroeder and Ryan D Ricks of Snell & Wilmer. 2 February 2021
Americas
More than 250 million rapid COVID-19 tests will be made available for low and middle-income countries as part of a World Health Organization initiative to accelerate the global response to the virus. 1 February 2021
Pharma
Biopharmaceutical company, Quercis Pharma, has exclusively licensed two patents to enhance its ability to provide approved treatments for COVID-19 and cancer. 28 January 2021
Americas
The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories, and Impax’s owner Amneal Pharmaceuticals, alleging that they were party to a 2017 agreement that violated antitrust law. 28 January 2021
Pharma
The US Court of Appeals for the Federal Circuit has dismissed an attempt by Valeant Pharmaceuticals to overturn a ruling that restricted where Hatch-Waxman Act patent lawsuits can be filed. 27 January 2021
Pharma
Reckitt Benckiser has dropped a $1.4bn claim against former subsidiary Indivior, which it filed following its record settlement with the US government over the marketing of an opioid treatment. 26 January 2021
Africa
Representatives of South Africa and India have again tried and failed to persuade the World Trade Organization to waive IP rights related to COVID-19 treatments and vaccinations. 25 January 2021
Pharma
A subsidiary of MSD has failed to revive a record $2.5bn verdict against Gilead Sciences, after the US Supreme Court refused to hear arguments that a patent was improperly invalidated. 21 January 2021